Abstract
The over-the-counter internal analgesic market is projected to nearly $3 billion in 2007. Shifting age demographics are helping the market, but growth has been sidetracked by controversial safety concerns. Brand marketers spend millions each year to launch brand extensions and delivery forms, but can new demand really be spurred in this mature market?
Mintel provides detailed analysis and insights, including consumer research commissioned especially for this report. Topics include:
- The impact of recent safety concerns on sales volume
- Why consumers limit their usage of pain relievers
- Why private label share is growing and how name brands can defend themselves
- How drugstores have increased their share of FDM sales
- Which maladies draw the highest percentage of consumers to OTC pain relief products
- Perceived differences among analgesic brands
- Where consumers go for information about OTC pain relievers
For the purposes of this report, the analgesics market is defined as including all oral analgesics, which are available over the counter without a prescription. Products intended for arthritis or migraine relief, and combination sleep aid/pain relief products, are also included. Products for children are covered, though they are not the main focus of this report.
Cold, cough and allergy remedies are excluded from this report, as are alertness aids and topical analgesics.
This report contains US IRI InfoScan data.
View Cart
